Carbetocin

Mechanism

A long-acting version of oxytocin used to prevent excessive bleeding after childbirth (postpartum hemorrhage). Unlike natural oxytocin which degrades quickly and needs refrigeration, carbetocin is heat-stable — making it practical for use in tropical, resource-limited settings. The WHO considers it an essential medicine for this reason. Also being studied as a nasal spray for autism.

Effects

**Reproductive System — Uterine (Tier 1 — Human Clinical):** Carbetocin is a long-acting synthetic analog of oxytocin with a half-life of approximately 40 minutes (vs 3–4 minutes for oxytocin). It binds uterine oxytocin receptors, producing sustained uterine contractions essential for postpartum hemostasis. A single 100 mcg IM dose produces uterine contraction equivalent to several hours of oxytocin infusion, making it ideal for postpartum hemorrhage prevention. **Cardiovascular (Tier 1 — Human Clinical):** Causes mild, transient facial flushing and may produce modest drops in blood pressure, but hemodynamic effects are generally less than oxytocin infusion due to the single-dose rather than continuous infusion approach. No significant cardiac effects at recommended doses. **Endocrine (Tier 2 — Human Clinical):** Promotes milk ejection reflex through central and peripheral oxytocin receptor activation. Supports early breastfeeding initiation. May have anxiolytic and bonding-promoting effects similar to oxytocin, though less studied. **Thermal Stability (Tier 1 — Pharmaceutical Property):** Heat-stable formulation developed for low-resource settings where cold chain maintenance is challenging. WHO added heat-stable carbetocin to the Essential Medicines List (2019) specifically for PPH prevention in settings without reliable refrigeration.

Practitioner Guide

**APPROVED INDICATION:** • Prevention of postpartum hemorrhage (PPH) following cesarean delivery (approved in many countries) and vaginal delivery (WHO recommendation 2018). • Approved in Europe, Canada, and many other countries. Not FDA-approved in the United States. **DOSING:** • Single dose: 100 mcg IV or IM, administered immediately after delivery (within 1 minute of placental delivery for cesarean; immediately after delivery for vaginal births). • No repeat dosing needed in most cases due to long half-life. • If additional uterotonic activity is needed, switch to oxytocin infusion rather than repeat carbetocin. **CLINICAL PEARLS:** • Key advantage over oxytocin: Single dose vs continuous infusion. This simplifies PPH prophylaxis, particularly in resource-limited settings and high-volume obstetric units. • The CHAMPION trial (WHO, >29,000 women) demonstrated non-inferiority of heat-stable carbetocin vs oxytocin for PPH prevention after vaginal delivery. This was a landmark trial leading to WHO Essential Medicines List inclusion. • Carbetocin should NOT be used for labor induction or augmentation — it is only for postpartum uterotonic therapy. • Contraindicated in preeclampsia/eclampsia patients with severe hypertension, hepatic or renal disease, and known hypersensitivity. • Unlike oxytocin, carbetocin does not require cold chain storage (heat-stable formulation), making it transformative for maternal health in developing nations.

Evidence

• Efficacy of carbetocin in the prevention of postpartum hemorrhage: a systematic review and Bayesian meta-analysis of randomized trials

  Erkan Kalafat et al. (2021) — J Matern Fetal Neonatal Med — PMID: 31537134

  Across 30 randomized trials, carbetocin reduced need for additional uterotonics versus oxytocin in cesarean delivery (RR 0.43, 95% CI 0.30-0.59) and in high-risk vaginal delivery (RR 0.56, 95% CI 0.34-0.94). In high-risk cesarean patients it also reduced postpartum blood transfusion risk (RR 0.57, 95% CI 0.33-0.96).

  strong

Research Summary

**Tier 1 (Human Clinical Evidence):** • CHAMPION trial (Lancet, 2018): >29,000 women across 10 countries. Heat-stable carbetocin was non-inferior to oxytocin for prevention of blood loss ≥500 mL after vaginal delivery. Led to WHO EML inclusion. • Multiple RCTs for cesarean section PPH prevention: Consistent evidence of non-inferiority to oxytocin with simplified administration. • Meta-analyses: Carbetocin is at least as effective as oxytocin for PPH prevention with fewer additional uterotonic interventions required. **Tier 2 (Strong Preclinical + Mechanistic):** • Pharmacokinetic profile well-characterized: half-life ~40 minutes (vs 3–4 minutes for oxytocin). Single-dose pharmacokinetics support once-only dosing strategy. • Receptor binding: Selective oxytocin receptor agonist with prolonged receptor occupancy due to enzymatic resistance (1-deamino modification prevents aminopeptidase degradation). **Tier 3 (Emerging / Theoretical):** • Potential CNS effects (anxiolysis, social bonding) analogous to oxytocin but with longer duration — not clinically investigated. • Investigation for other oxytocin-responsive conditions (autism spectrum social deficits, PTSD) is theoretically possible but no trials initiated.